Safety Implementations Table of Contents 1 Abstract 4 2 Introduction 5 3 Safe Drug Development Process in Pharmaceutical Companies 6 4 Pharmaceutical Unit Operation Safety Measures 10 4.1 Weighing and dispensing 10 4.2 Charging and discharging 10 4.3 Liquid separations 10 4.4 Filtration 11 4.5 Compounding 11 4.6 Drying 11 5 Biosafety Levels 12 5.1 Level 1 12 5.2 Level 2 12 5.3 Level 3 12 5.4 Level 4 13 6 Personal Protective Equipment 13 6.1 What is PPE? 13 6.2 OSHA Standards
Premium Occupational safety and health Personal protective equipment Pharmaceutical industry
A. Introduction Pfizer‚ US pharmaceutical company is one of the largest pharmaceutical companies in the world. Unfortunately‚ Pfizer faced challenges by macro-environment forces that affect their sales volume decline dramatically in 2011. PESTEL‚ Porter’s Five Forces and Industry Lift Cycle frameworks to be applied to analysis the broad macro-environment that affected Pfizer in the pharmaceutical industry. 1. PESTEL framework PESTEL (Appendix I) is classifies into six environmental influences
Premium Pharmaceutical industry Pharmacology Food and Drug Administration
Pharmaceutical Marketing Merck “Merck has gone beyond developing and selling prescription pharmaceuticals. It formed joint ventures in 1989 with Johnson & Johnson to sell over the-counter pharmaceuticals; in 1991 with DuPont to expand basic research‚ and in 2000 with Scherigng-Plough to develop and market new prescriptions medicines. In 1997‚ Merck and Rhone-Poulenc S.A. (now Sanofi-Aventis S.A.) combined animal health and poultry genetics business to form Merial Limited‚ a fully integrated
Premium Pharmaceutical industry Pharmacology Clinical trial
Cooper Pharmaceuticals Inc BMKT 436: Sales and Sales Management Shaye Murphy 10/12/2013 Executive Summary Goals Cooper Pharmaceuticals Inc (CPI) is a major manufacturer for the dental and medical practices in the United States. Their ultimate goal is to remain the largest drug manufacturer and meet the sales quotas. CPI has strong ethical policies that they want to keep that have shaped the companies’ reputation. In hiring Bob Marsh‚ they were meeting their goals
Premium Sales Customer service Marketing
Introduction In 1973‚ the UK based multinational pharmaceutical company‚ ICI plc. Established a subsidiary in Dhaka‚ known as ICI Bangladesh Manufacturers Limited. In 1992‚ ICI plc. divested its share to local management‚ and the company was renamed Advanced Chemical Industries (ACI) Limited. ACI formulates and markets a comprehensive range of more than 387 products covering all major therapeutic areas‚ which come in tablet‚ capsule‚ powder‚ liquid‚ cream‚ ointment‚ gel ‚ophthalmic and injection
Premium ISO 9000 Quality management Quality assurance
Incumbent Company: Dr. Reddy’s Laboratories ¬¬¬ Indian Pharmaceutical Industry can be valued at around $20billion (2009). By Volume‚ India is world’s second largest producer of pharmaceuticals‚ while by value it is world’s thirteenth largest. It is expected to grow at CAGR of 12% for 2010-2012 (global average 6%).Around 95% of Domestic demand is catered by Indian Pharmaceutical companies. In Indian Pharmaceuticals Market‚ Formulations accounted for 65% while Bulk Drugs accounted for 35% by
Premium Generic drug Pharmaceutical industry Pharmacology
Presentation on Beximco Pharmaceuticals Name of the presenters ~ Faisal Bin Kamal 2009-3-10-057 2010-1-10-145 2010-1-10-149 2010-1-40-052 ~ Quazi Aritra Reyan ~ Md. Nayeem Hossain ~ Tahrim Shahriar Background of the Company Beximco Pharmaceuticals (BPL) is a leading edge pharmaceutical company based in Dhaka‚ Bangladesh. BPL started its operation in 1980 and now have grown to become nation’s one of the leading pharmaceutical companies. ~ BPL supplies more than 10% of country’s
Premium Pharmaceutical industry Tax Balance sheet
cardiovascular disorders‚ antibiotics such as Cefzil‚ antidiabetics such as Glucophage‚ and the anti-clotting medication‚ Plavix. To continue to focus on pharmaceuticals‚ in the early years of 2000-2002‚ the company divested many of their non-pharmaceutical divisions‚ such as Clairol and the Mead-Johnson Nutritional division‚ and purchased DuPont Pharmaceuticals as well as an almost 20% share of ImClone Systems‚ which was getting ready to release a new anti-cancer drug‚ Erbitux (SEC eyes Bristol-Myers‚ 2002)
Premium Revenue Marketing Inventory
Centralized vs. Decentralized Misablaci Pharmaceutical can perform as a centralized or a decentralized organization. Many factors will determine whether Misablaci Pharmaceutical will employ centralized or decentralized operations. Since Misablaci Pharmaceutical is a large organization extending out globally both centralized and decentralized can be utilize. The company will perform in the centralized mode more effectively in the global operations. In centralization limited authority is given
Premium Management Organization Strategic management
Chapter 3 Closing Case: The Pharmaceutical Industry Historically‚ the pharmaceutical industry has been a profitable one. Between 2002 and 2006 the average rate of return on invested capital (ROIC) for firms in the industry was 16.45 percent. Put differently‚ for every dollar of capital invested in the industry‚ the average pharmaceutical firm generated 16.45 cents of profit. This compares with an average return on invested capital of 12.76 percent for firms in the computer hardware industry‚
Premium Pharmacology Generic drug Pharmaceutical industry